Trial · NCT06275919
Regorafenib for Recurrent Meningioma (MIRAGE Trial)
NCT06275919, Phase 2, Recruiting, Istituto Oncologico Veneto IRCCS
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Regorafenib for Recurrent Meningioma (MIRAGE Trial). Trials, record NCT06275919. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06275919
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Regorafenib for Recurrent Meningioma (MIRAGE Trial)
- NCT number
- NCT06275919
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 104 participants, estimated
- Lead sponsor
- Istituto Oncologico Veneto IRCCS
- Conditions
- Meningioma, Malignant
- Interventions
- Regorafenib 40 MG Oral Tablet, Local Standard of Care
- First posted
- 2024-02-23
- Last updated
- 2026-09-30
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression free survival (PFS) | Up to 54 months | The progression free survival (PFS) will be determined as the time from the date of enrolment to the date of disease progression determined using RANO criteria or to the date of death, whichever occurs first. |
| Secondary | Overall survival (OS) | Up to 42 months | The overall survival (OS) will be determined as the time from the date of enrolment to the date of death from any cause. |
| Secondary | Objective response rate (ORR) | Up to 42 months | The objective response rate (ORR) will be defined as the percentage of patients with complete response (CR) and partial response (PR) determined using modified Macdonald criteria. |
| Secondary | Patient Reported Outcomes (PROs) | Up to 42 months | Quality of life will be assessed by EORTC QLQ-C30 questionnaire. |
| Secondary | Patient Reported Outcomes (PROs) | Up to 42 months | Quality of life will be assessed by the QLQBN20 questionnaire. |
| Secondary | Toxicity during treatment | Up to 42 months | Toxicity during the treatment will be recorded and graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v.5. |
| Secondary | Disease control rate (DCR) | Up to 42 months | The disease control rate (DCR) will be defined as the percentage of patients with complete response (CR), partial response (PR) and stable disease (SD) determined using modified Macdonald criteria. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40759981 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06275919
GET https://conductscience.org/api/trials/v1/NCT06275919/registered